ImmunomeInc Non Current Assets Total vs Common Stock Shares Outstanding Analysis
| IMNM Stock | USD 14.94 0.23 1.56% |
ImmunomeInc financial indicator trend analysis is infinitely more than just investigating ImmunomeInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmunomeInc is a good investment. Please check the relationship between ImmunomeInc Non Current Assets Total and its Common Stock Shares Outstanding accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.
Non Current Assets Total vs Common Stock Shares Outstanding
Non Current Assets Total vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmunomeInc Non Current Assets Total account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have weak relationship.
The correlation between ImmunomeInc's Non Current Assets Total and Common Stock Shares Outstanding is 0.33. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of ImmunomeInc, assuming nothing else is changed. The correlation between historical values of ImmunomeInc's Non Current Assets Total and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of ImmunomeInc are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Current Assets Total i.e., ImmunomeInc's Non Current Assets Total and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.33 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from ImmunomeInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmunomeInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.At this time, ImmunomeInc's Selling General Administrative is very stable compared to the past year. As of the 2nd of June 2024, Enterprise Value is likely to grow to about 121.1 M, while Issuance Of Capital Stock is likely to drop about 29.1 K.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 503K | 728K | 689.9K | Interest Income | 5K | 2.7M | 2.9M |
ImmunomeInc fundamental ratios Correlations
Click cells to compare fundamentals
ImmunomeInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmunomeInc fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
| Short Long Term Debt Total | 564K | 613K | 317K | 293K | 1.7M | 845.7K | |
| Other Current Liab | 666K | 1.4M | 6.7M | 4.6M | 7.7M | 3.9M | |
| Total Current Liabilities | 1.7M | 3.0M | 9.7M | 7.3M | 21.8M | 22.9M | |
| Total Stockholder Equity | (35.6M) | 41.3M | 48.2M | 16.7M | 119.9M | 125.9M | |
| Net Tangible Assets | (35.6M) | 41.3M | 48.2M | 16.7M | 19.2M | 10.0M | |
| Property Plant And Equipment Net | 1.7M | 1.5M | 855K | 965K | 3.6M | 2.0M | |
| Net Debt | (2.0M) | (39.2M) | (48.9M) | (20.0M) | (97.0M) | (92.2M) | |
| Retained Earnings | (36.6M) | (54.4M) | (79.1M) | (116.0M) | (222.8M) | (211.7M) | |
| Accounts Payable | 548K | 1.2M | 3.1M | 2.4M | 3.3M | 2.0M | |
| Cash | 2.5M | 39.8M | 49.2M | 20.3M | 98.7M | 103.6M | |
| Non Current Assets Total | 1.9M | 1.6M | 1.3M | 1.4M | 3.8M | 2.3M | |
| Cash And Short Term Investments | 2.5M | 39.8M | 49.2M | 20.3M | 138.1M | 145.0M | |
| Common Stock Shares Outstanding | 5.7M | 3.4M | 11.5M | 12.1M | 19.8M | 10.5M | |
| Liabilities And Stockholders Equity | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
| Non Current Liabilities Total | 39.0M | 142K | 12K | 62K | 6.8M | 9.9M | |
| Capital Lease Obligations | 239K | 0.0 | 317K | 293K | 1.7M | 1.7M | |
| Other Current Assets | 579K | 3.1M | 7.4M | 2.3M | 6.3M | 3.7M | |
| Other Stockholder Equity | 927K | 95.7M | 127.3M | 132.7M | 342.7M | 359.8M | |
| Total Liab | 40.7M | 3.2M | 9.7M | 7.4M | 28.7M | 15.9M | |
| Net Invested Capital | (35.3M) | 42.0M | 48.2M | 16.7M | 119.9M | 125.9M | |
| Property Plant And Equipment Gross | 1.7M | 1.5M | 3.9M | 681K | 7.5M | 7.9M | |
| Total Current Assets | 3.1M | 42.9M | 56.6M | 22.6M | 144.7M | 151.9M | |
| Accumulated Other Comprehensive Income | (38.9M) | (44.5M) | (57.9M) | 0.0 | 22K | 23.1K | |
| Net Working Capital | 1.5M | 39.9M | 46.9M | 15.3M | 122.9M | 129.0M | |
| Short Term Debt | 451K | 479K | 317K | 293K | 310K | 328.3K | |
| Property Plant Equipment | 1.7M | 1.5M | 855K | 681K | 612.9K | 1.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as ImmunomeInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunomeInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for ImmunomeInc Stock analysis
When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.58) | Revenue Per Share 0.427 | Quarterly Revenue Growth (0.56) | Return On Assets (0.15) | Return On Equity (1.55) |
The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.